ProShares Trust - ProShares Short Dow30 -1x Shares
DOG
Get informed when a big investor buys or sells
+ FollowMarket Cap$39.35B
Close$
Share Statistics
| Market cap | $39.35 Billion |
|---|---|
| Enterprise Value | $39.17 Billion |
| Dividend Yield | $0.73 (3.38%) |
| Earnings per Share | $- |
| Beta | -0.82 |
| Outstanding Shares | - |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2999.97 |
| Enterprise Value to EBIT | -521.18 |
| Enterprise Value to Net Income | -556 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0374▲ 103.74% |
|---|---|
| Total Calls | 34,800▲ Infinity% |
| Total Puts | 36,100▼ 0.82% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 36.90%▲ 23.21% |
|---|---|
| Total Invested | $46.23M▲ 180.30% |
| Investors Holding | 35▲ 12.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...